MLYS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Mineralys Therapeutics Inc (MLYS) is not a strong buy at the moment for a beginner investor with a long-term strategy. While hedge funds are showing significant interest and analysts have a positive outlook with a raised price target, the company's financial performance is weak, and there are no recent news catalysts or strong trading signals to support an immediate buy decision. The technical indicators and options data also do not suggest a compelling entry point right now.
The MACD histogram is positive but contracting, indicating a weakening upward momentum. RSI is neutral at 47.033, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level of 28.818, with key resistance at 30.88 and support at 26.755.
Hedge funds have significantly increased their buying activity by 516.79% over the last quarter. Analysts have raised the price target to $51, citing underappreciated sales potential for the lead drug lorundrostat.
The company's financials are weak, with a significant drop in net income (-34.14% YoY) and EPS (-59.18% YoY). There is no recent news or congress trading data to act as a positive catalyst.
In Q4 2025, the company reported no revenue growth (0% YoY), a net income loss of -$32.23 million (-34.14% YoY), and an EPS drop to -0.4 (-59.18% YoY). Gross margin remains at 0%.
BofA has raised the price target to $51 from $46 and maintains a Buy rating, citing underappreciated peak sales potential for lorundrostat.
